Entourage Health (ENTG) Q2 2024 earnings summary

Executive summary

• Q2 2024 was marked by heightened competition, pricing pressures, and oversupply, leading to a more consolidated cannabis market.

• Revenue for Q2 2024 was $12.2M, down 9% year-over-year, while six-month revenue rose 1% to $28.6M.

• Net loss for Q2 2024 was $10.3M, compared to $9.6M in Q2 2023; six-month net loss was $16.6M, an improvement from $19.1M last year.

• Strategic focus has shifted to distribution expansion, product innovation, and operational efficiency to drive sustainable growth.

• Material uncertainty exists regarding going concern due to significant debt, covenant breaches, and negative working capital.

Financial highlights

• Q2 2024 total revenue decreased by CAD 1.1 million (9%) to CAD 12.2 million year-over-year; net revenue fell by CAD 0.9 million (9%) to CAD 9.3 million.

• Gross profit before changes in fair value for Q2 2024 was $0.7M (8% of net revenue), down from $2.2M (21%) in Q2 2023.

• SG&A expenses dropped by CAD 2.1 million (31%) year-over-year, reflecting restructuring and cost-saving initiatives.

• Q2 2024 EBITDA was $(3.2)M, a slight improvement year-over-year; six-month EBITDA was $4.3M, up 159%.

• Cash at June 30, 2024 was $2.6M, down from $11.2M at year-end; working capital deficit widened to $163.2M.

Outlook and guidance

• Management remains focused on cash preservation, operational efficiency, and adapting to market conditions.

• The company is committed to margin amplification, revenue growth, and product innovation for 2024 and beyond.

• Focus remains on operational excellence, cost reduction, and automation to drive long-term EBITDA margin to 10% of net revenues.

• The company is pursuing additional financing, asset monetization, and strategic partnerships to address liquidity.